ramatroban has been researched along with Coronary Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fiedler, VB; Perzborn, E; Seuter, F | 1 |
| Böshagen, H; Fiedler, VB; Perzborn, E; Rosentreter, U; Seuter, F | 1 |
2 other study(ies) available for ramatroban and Coronary Disease
| Article | Year |
|---|---|
Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Carbazoles; Coronary Disease; Coronary Vessels; Disease Models, Animal; Dogs; Hemodynamics; Myocardial Infarction; Prostaglandin Endoperoxides, Synthetic; Sulfonamides; Swine; Thromboxanes; Vasoconstriction | 1990 |
Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
Topics: Animals; Blood Pressure; Carbazoles; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Dogs; Electric Stimulation; Female; Fibrinolytic Agents; Heart Rate; Humans; In Vitro Techniques; Male; Myocardial Infarction; Sulfonamides; Thromboxane A2 | 1989 |